Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan

Taro Funakoshi¹, Takahiro Horimatsu¹, Michio Nakamura², Koichi Shiroshita³, Koichi Suyama⁴, Masashi Mukoyama⁵, Takuro Mizukami⁶, Tsutomu Sakurada⁷, Eishi Baba⁸, Kazuhiko Tsuruya⁹, Akira Nozaki¹⁰, Kensei Yahata¹¹, Yukinori Ozaki¹², Yoshifumi Ubara¹³, Hisateru Yasui¹⁴, Akihiro Yoshimoto¹⁵, Shingo Fukuma¹⁶, Naoya Kondo¹⁷, Takeshi Matsubara¹⁷, Kazuo Matsubara¹⁸, Shunichi Fukuhara¹⁹, Motoko Yanagita¹⁷, Manabu Muto¹

Affiliations

¹ Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
² Department of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan.
³ Division of Nephrology, Sapporo City General Hospital, Sapporo, Japan.
⁴ Kumamoto University Hospital Cancer Center, Kumamoto University, Kumamoto, Japan.
⁵ Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.
⁶ Department of Clinical Oncology, St Marianna University School of Medicine, Kawasaki, Japan.
⁷ Division of Nephrology and Hypertension, Department of Internal Medicine, St Marianna University School of Medicine, Kawasaki, Japan.
⁸ Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
⁹ Department of Integrated Therapy for Chronic Kidney Disease, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
¹⁰ Department of Clinical Oncology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
¹¹ Department of Nephrology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
¹² Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
¹³ Nephrology Center, Toranomon Hospital, Tokyo, Japan.
¹⁴ Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
¹⁵ Department of Nephrology, Kobe City Medical Center General Hospital, Kobe, Japan.
¹⁶ Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto University, Kyoto, Japan.
¹⁷ Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
¹⁸ Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
¹⁹ Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.

PMID: 29531838
PMCID: PMC5844381
DOI: 10.1136/esmoopen-2017-000301

Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan

Taro Funakoshi et al. ESMO Open. 2018.

. 2018 Feb 23;3(2):e000301.

doi: 10.1136/esmoopen-2017-000301. eCollection 2018.

Authors

Affiliations

¹ Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
² Department of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan.
³ Division of Nephrology, Sapporo City General Hospital, Sapporo, Japan.
⁴ Kumamoto University Hospital Cancer Center, Kumamoto University, Kumamoto, Japan.
⁵ Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.
⁶ Department of Clinical Oncology, St Marianna University School of Medicine, Kawasaki, Japan.
⁷ Division of Nephrology and Hypertension, Department of Internal Medicine, St Marianna University School of Medicine, Kawasaki, Japan.
⁸ Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
⁹ Department of Integrated Therapy for Chronic Kidney Disease, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
¹⁰ Department of Clinical Oncology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
¹¹ Department of Nephrology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
¹² Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
¹³ Nephrology Center, Toranomon Hospital, Tokyo, Japan.
¹⁴ Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
¹⁵ Department of Nephrology, Kobe City Medical Center General Hospital, Kobe, Japan.
¹⁶ Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto University, Kyoto, Japan.
¹⁷ Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
¹⁸ Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
¹⁹ Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.

PMID: 29531838
PMCID: PMC5844381
DOI: 10.1136/esmoopen-2017-000301

Abstract

Background: Cancer is a major cause of death in patients undergoing haemodialysis. However, information about the actual clinical practice of chemotherapy for patients with cancer undergoing haemodialysis is lacking. We conducted a nationwide survey using questionnaires on the clinical practice of chemotherapy for such patients.

Patients and methods: The nationwide survey included patients undergoing haemodialysis who were subsequently diagnosed with cancer in 20 hospitals in Japan from January 2010 to December 2012. We reviewed their clinical data, including cancer at the following primary sites: kidney, colorectum, stomach, lung, liver, bladder, pancreas and breast. The questionnaires consisted of the following subjects: (1) patient characteristics; (2) regimen, dosage and timing of chemotherapy; and (3) clinical outcome.

Results: Overall, 675 patients were registered and assessed for main primary cancer site involvement. Of 507 patients with primary site involvement, 74 patients (15%) received chemotherapy (44 as palliative chemotherapy and 30 as perioperative chemotherapy). The most commonly used cytotoxic drugs were fluoropyrimidine (15 patients), platinum (8 patients) and taxane (8 patients), and the dosage and timing of these drugs differed between institutions; however, the dosage of molecular targeted drugs (24 patients) and hormone therapy drugs (15 patients) was consistent. The median survival time of patients receiving palliative chemotherapy was 13.0 months (0.1-60.3 months). Three patients (6.8%) died from treatment-related causes and nine patients (20%) died of causes other than cancer. Of the 30 patients who received perioperative chemotherapy, 6 (20%) died of causes other than cancer within 3 years after the initiation of chemotherapy.

Conclusion: Among the haemodialysis patients with cancer who received chemotherapy, the rates of mortality from causes other than cancer might be high for both palliative and perioperative chemotherapy. Indications for the use of chemotherapy in patients undergoing haemodialysis should be considered carefully.

Keywords: anticancer drug; chemotherapy; dosage adjustment; end-stage renal disease; hemodialysis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MN has received honoraria from Daiichi Sankyo and Taiho Pharmaceutical. MasM has received research grants from Chugai, Kyowa Hakko Kirin, Takeda, Daiichi Sankyo, Astellas, Otsuka, Baxter, Teijin Pharma and Shionogi. TS has received research grants from Baxter, Astellas, Kyowa Hakko Kirin, Teijin Pharma and Takeda. EB has received research grants from Takeda, Chugai, Eli Lilly, Merck Serono, Shionogi and Taiho. He has also received honorarium from Eli Lilly. KT has received research grants from Kyowa Hakko Kirin, Chugai, Takeda, Kissei, Otsuka, Daiichi Sankyo and Torii. He has also received honoraria from Kyowa Hakko Kirin, Chugai and Sanofi. His institution has received funding from Baxter. AN has received research grant from Daiichi Sankyo. HY has received honoraria from Medicon, Taiho, Chugai, Yakult Honsha, Bristol-Myers Squibb, Takeda and Kyowa Hakko Kirin. MY has been on the advisory board of Astellas and received research grants from Astellas, Chugai, Daiichi Sankyo, Fuji Yakuhin, Kyowa Hakko Kirin, Mitsubishi Tanabe, MSD, Nippon Boehringer Ingelheim, Baxter, Takeda Pharmaceutical Company, Fuso Pharmaceutical Industries and Terumo Corporation. ManM has received research grant from Chugai, Yakult Honsha, Ono Pharmaceutical, Ayumi Pharmaceutical, Showa Yakuhin Kako, Shionogi, Taiho, Terumo and Nippon Zoki Pharmaceutical Corporations.

Figures

**Figure 1**
Kaplan-Meier curves for overall survival: (A) palliative group and (B) perioperative group.

See this image and copyright information in PMC

Cited by

Monitoring antibody binding to T cells in a pembrolizumab-treated patient with lung adenocarcinoma on hemodialysis.
Osa A, Uenami T, Naito Y, Hirata H, Koyama S, Takimoto T, Shiroyama T, Futami S, Nakatsubo S, Sawa N, Yano Y, Nagatomo I, Takeda Y, Mori M, Kida H, Kumanogoh A. Osa A, et al. Thorac Cancer. 2019 Nov;10(11):2183-2187. doi: 10.1111/1759-7714.13197. Epub 2019 Sep 14. Thorac Cancer. 2019. PMID: 31520515 Free PMC article.
Onco-nephrology in clinical practice: pharmacokinetics, monitoring, and treatment strategies for patients with cancer and impaired renal function.
Nakagawa S, Ikuta K, Masuda T, Terada T. Nakagawa S, et al. Int J Clin Oncol. 2025 Sep;30(9):1700-1706. doi: 10.1007/s10147-025-02832-z. Epub 2025 Jul 17. Int J Clin Oncol. 2025. PMID: 40676437 Free PMC article. Review.
Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials.
Sprangers B, Perazella MA, Lichtman SM, Rosner MH, Jhaveri KD. Sprangers B, et al. Kidney Int Rep. 2022 Jun 15;7(9):1939-1950. doi: 10.1016/j.ekir.2022.06.005. eCollection 2022 Sep. Kidney Int Rep. 2022. PMID: 36090489 Free PMC article. Review.
How I treat cancer special issue.
Zielinski CC. Zielinski CC. ESMO Open. 2019 May 1;4(Suppl 2):e000514. doi: 10.1136/esmoopen-2019-000514. eCollection 2019. ESMO Open. 2019. PMID: 31231575 Free PMC article. No abstract available.
Resource Oriented Decision Making for Treatment of Metastatic Colorectal Cancer (mCRC) in a Lower-Middle Income Country: Egyptian Foundation of Medical Sciences (EFMS) Consensus Recommendations 2020.
Rashad N, Abdulla M, Farouk M, Elkerm Y, Eid Salem S, Yahia M, Saad AS, Abdel Aziz AH, Refaat G, Awad I, ElNaggar M, Kamal K, Refky B, Abdelkhalek M, Touny A, Kassem L, Shash E, Abdelhay AA, Mahmoud BE, Oualla K, Chraiet N, AwadElkarim H Maki H, Kader YA. Rashad N, et al. Cancer Manag Res. 2022 Feb 28;14:821-842. doi: 10.2147/CMAR.S340030. eCollection 2022. Cancer Manag Res. 2022. PMID: 35250310 Free PMC article.

See all "Cited by" articles

References

1. Liyanage T, Ninomiya T, Jha V, et al. . Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015;385:1975–82. 10.1016/S0140-6736(14)61601-9 - DOI - PubMed
1. Masakane I, Nakai S, Ogata S, et al. . An overview of regular dialysis treatment in Japan (As of 31 December 2013). Ther Apher Dial 2015;19:540–74. 10.1111/1744-9987.12378 - DOI - PubMed
1. Maisonneuve P, Agodoa L, Gellert R, et al. . Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999;354:93–9. 10.1016/S0140-6736(99)06154-1 - DOI - PubMed
1. de Jager DJ, Grootendorst DC, Jager KJ, et al. . Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009;302:1782–9. 10.1001/jama.2009.1488 - DOI - PubMed
1. Kitai Y, Matsubara T, Yanagita M. Onco-nephrology: current concepts and future perspectives. Jpn J Clin Oncol 2015;45:617–28. 10.1093/jjco/hyv035 - DOI - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan

Affiliations

Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Other Literature Sources